Investor Presentation - First Six Months of 2021
69
Investor presentation First six months of 2021
Novo NordiskⓇ
Haemophilia is a rare disease with severe unmet medical needs
and the market is highly competitive
Number of Low diagnosis and treatment rates
within haemophilia
DKK billion
Sales of recombinant haemophilia products
people (000)
500
400
300
200
100
0
People with
haemophilia
Diagnosed
Haemophilia A Haemophilia B
40
40
30
30
20
20
10
0
Inhibitor
2016 2020
2016
Haemophilia
with inhibitors
NovoSevenⓇ
Coagil VII
Obizur¹
2020
Haemophilia A
2016
NovoEight®
2020
Haemophilia B
RefixiaⓇ/RebinynⓇ
Advate/Adynovate
Idelvion
Kogenate/Kovaltry/Jivi
Rixubis
Feiba²
Hemlibra³
Xyntha/Refacto
Alprolix
Eloctate/Elocta
Benefix
Helixate/Afstyla
Hemlibra
Note: The inhibitor segment includes acquired haemophilia patients, patients with low titre inhibitors or with transient
inhibitors, and patients on immune tolerance induction.
Source: World Federation of Haemophilia (WFH) - Annual survey 2018; WFH: Closing the gap - achieving optimal care,
Haemophilia 2012.
1 Obizur only indicated for acquired haemophilia; 2 Plasma-derived; 3 Part of the Hemlibra sales is used for treatment of
haemophilia A patients in 2020
Source: Company reported sales and EvaluateView entire presentation